Nephrodi Therapeutics, Inc.

Seattle, WA

UEI
KZLUNSSJLA83
CAGE
84S44
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2200 32nd Ave W, Seattle, WA 98199, USA
Website
nephrodi.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Novel ampk activator for treatment of congenital x-linked nephrogenic diabetes insipidus in pediatric patients R44DK127798 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $2,095,545
Novel ampk activators for the treatment of lithium-induced nephrogenic diabetes insipidus R41DK127798 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $297,609

Quick answers

Is Nephrodi Therapeutics, Inc. registered in SAM.gov?

Yes. Nephrodi Therapeutics, Inc.'s SAM.gov registration is active through May 20, 2027.

What is Nephrodi Therapeutics, Inc.'s most recent federal award?

Nephrodi Therapeutics, Inc.'s most recent federal grant award is Novel ampk activator for treatment of congenital x-linked nephrogenic diabetes insipidus in pediatric patients (R44DK127798), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 15, 2020.

On GovTribe

See Nephrodi Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login